Top

Published in:

Open Access 01-03-2012 | Perspectives

The economic pressures for biosimilar drug use in cancer medicine

Author: Paul Cornes

Published in: Targeted Oncology | Special Issue 1/2012

Abstract

The main rationale for using biosimilar drugs is for cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations, medical insurers and individuals and the absolute savings that could be gained by switching from original drugs. This paper is designed to discover the degree to which financial constraints will drive future health spending and to discover if legal or safety issues could impact on any trend. A structured literature search was performed for papers and documents to 27 August 2011. Where multiple sources of data were available on a topic, data from papers and reports by multinational or national bodies were used in preference to data from regions or individual hospitals. Almost all health systems face current significant cost pressures. The twin driver of increasing cancer prevalence as populations age and cancer medicine costs rising faster than inflation places oncology as the most significant single cost problem. For some countries, this is predicted to make medicine unaffordable within a decade. Most developed countries have planned to embrace biosimilar use as a cost-control measure. Biosimilar introduction into the EU has already forced prices down, both the price of biosimilar drugs and competitive price reductions in originator drugs. Compound annual growth rates of use have been predicted at 65.8% per year. Most developed countries have planned to embrace biosimilar use as a major cost-control measure. Only legal blocks and safety concerns are likely to act against this trend. For centralised healthcare systems, and those with a strong tradition of generic medicine use, biosimilar use will clearly rise with predictions of more than 80% of prescriptions of some biologic drugs within 1 year of market entry in the USA. Delaying the implementation of such programmes however risks a real crisis in healthcare delivery for many countries and hospitals that few can now afford.

Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533–43PubMedCrossRef

http://www.usatoday.com/news/health/2008-12-09-cancer_N.htm

Mulcahy N (2009) Time to consider cost in evaluating cancer drugs in United States? Medscape Medical News July 14. http://www.medscape.com/viewarticle/705689

Behnke N, Hueltenschmidt N, Pasternak A, Singh K (2011) Biosimilars: a marathon, not a sprint. Industry Brief 12/16/09. http://www.bain.com/bainweb/publications/publications_detail.asp?id=27518&menu_url=publications_results.asp

Medicare Payment Advisory Commission: report to the Congress: Medicare Payment Policy, (3, 2010) (Washington, DC). Available at http://www.medpac.gov/documents/Mar10_EntireReport.pdf. Accessed 3 March 2011

Medical Subject Headings (MeSH) portal of the USA National Library of Congress PubMed database. Available at http://www.ncbi.nlm.nih.gov/mesh

PubMed. http://www.ncbi.nlm.nih.gov/pubmed?term=biosimilar

Google “related sites” programme. Available at http://www.google.com/help/features.htmlwebportal

Schwartz K (2010) Projected costs of chronic diseases. Health Care Cost Monitor. January 22

10.

WHO (2008) Cancer to be world’s top killer by 2010. USA Today, 12/9/2008. Available from http://www.usatoday.com/news/health/2008-12-09-cancer_N.htm. Accessed 13 March 2011

11.

http://www.breakingnews.ie/archives/2006/0607/ireland/potentially-fatal-cancer-cases-predicted-to-double-by-2020-262312.html

12.

Ibrahim E, Bin SB, Banjar L et al (2008) Current and future cancer burden in Saudi Arabia: meeting the challenge. Hematol Oncol Stem Cell Ther 1(4):210–5PubMed

13.

The Rising Cost of Cancer Care: Who Takes Responsibility? J Multidisciplinary Cancer Care. October 2010, Vol 3, no 7. Available at http://www.jomcc.com/article/rising-cost-cancer-care-who-takesresponsibility. Accessed 13 march 2011

14.

Cost of US healthcare (1980) US News and World Report Magazine. Sept 1st

15.

Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group, Historical; NHE summary including share of GDP, CY 1960–2007. http://www.cms.hhs.gov/NationalHealthExpendData/(see Historical; NHE summary including share of GDP, CY 1960–2007; file nhegdp07.zip). Accessed 22 Feb 2011

16.

Goldman DP, McGlynn EA (2005) US Health Care—Facts about cost, access, and quality. The RAND Corporation 2005. Available at http://www.rand.org/pubs/corporate_pubs/2005/RAND_CP484.1.pdf. Accessed 13 March 2011

17.

Ward E, Halpern M, Schrag N et al (2008) Association of insurance with cancer care utilization and outcomes. CA Cancer J 58:9–31CrossRef

18.

Nelson R (2011) Medicare unable to control rising costs of cancer care. Medscape Medical News. Available at http://www.medscape.com/viewarticle/587974. Accessed 13 march 2011

19.

Auguste BG, Laboissière M, Mendonca LT (2009) How health care costs contribute to income disparity in the United States. McKinsey Quarterly (April)

20.

Noah T (2011) Health haves and have- nots. The true cost of spiraling medical inflation. Slate Magazine. http://www.slate.com/id/2216431/. Accessed 6 March 2011

21.

http://www.mckinseyquarterly.com/How_health_care_costs_contribute_to_income_disparity_in_the_United_States_2328. Accessed 6 March 2011

22.

Employer Health Benefits 2009 Annual Survey, Kaiser Family Foundation and Health Research Educational Trust

23.

Cavallo J (2011) Containing the high cost of cancer care. Four experts examine the issue and offer solutions. The ASCO Post, February 15, 2011, Volume 2, Issue 3

24.

Himmelstein DU, Thorne D, Warren E et al (2009) Medical bankruptcy in the United States, 2007: results of a national study. Am J Med 122:741–6PubMedCrossRef

25.

Malin JL (2010) Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society’s willingness to pay? J Clin Oncol 28(20):3212–4PubMedCrossRef

26.

Keehan S, Sisko A, Truffer C, et al. (2008) Health spending projections through 2017: the baby-boom generation is coming to medicare. Health Aff March 27: w145–w55; published ahead of print February 26. doi:10.1377/hlthaff.27.2.w145. Accessed 22 Feb 2011

27.

Chernew ME, Hirth RA, Cutler DM (2009) Increased spending on health care: longterm implications for the Nation. Health Aff 28(5):1253–5CrossRef

28.

WHO—Spectre of ageing population worries economistsBulletin of the World Health Organization 88(3). Available at http://www.who.int/bulletin/volumes/88/3/10-030310/en/index.html

29.

Schickedanz A (2010) Of value: a discussion of cost, communication, and evidence to improve cancer care. Oncologist 15(Suppl 1):73–9PubMedCrossRef

30.

Adams CP, Brantner VV (2006) Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25:420–8CrossRef

31.

Rucker NL (2007) Biologics in perspective: expanded clinical options amid greater cost scrutiny. AARP (online)

32.

Hillner BE, Smith TJ (2009) Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27:2111–3PubMedCrossRef

33.

Perrin S (2010) Therapeutic decision making in oncology. Hosp Pharm Eur 52:36–7

34.

Sarin R (2008) Criteria for deciding costeffectiveness for expensive new anticancer agents. J Can Res Ther 4:1–2CrossRef

35.

Bach P (2009) Limits on medicare’s ability to control rising spending on cancer drugs. N Engl J Med 360:626–33PubMedCrossRef

36.

Fojo T, Grady C (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101(15):1044–8PubMedCrossRef

37.

“Is the price of cancer treatment falling?” Paper presented at the annual meeting of the economics of population health: Inaugural Conference of the American Society of Health Economists, TBA, Madison, WI, USA, Jun 04, 2006. Available http://www.allacademic.com/meta/p93517_index.html, Accessed 12 March 2011

38.

Schrag D (2004) NEJM 351:317–9PubMedCrossRef

39.

Jansman FGA, Maarten J, Postma MJ, Brouwers JRBJ (2007) PharmacoEconomics 25(7):537–62PubMedCrossRef

40.

Uyl-de Groot CA, de Groot S, Steenhoek A (2010) The economics of improved cancer survival rates: better outcomes, higher costs. Expert Rev Pharmacoeconomics Outcomes Res 10(3):283–92CrossRef

41.

Wilking N, Jönsson B (2011) A pan- European comparison regarding patient access to cancer drugs. Available at http://ki.se/content/1/c4/33/16/Cancer_Report.pdf. Accessed 13 March 2011

42.

US National Cancer Institute website for cancer prevalence and cost of care projection data. Available at http://costprojections.cancer.gov/graph.php. Accessed 3 March 2011

43.

Cancer Network (2011) NIH study predicts the cost of cancer care will increase 27% by 2020. Cancer Network, January 12. http://www.cancernetwork.com/practice/content/article/10165/1776564

44.

The relative effect of demographics and increased unit treatment costs on the spending on Medicare, Medicaid and Social Security as a% of USA GDP. Office of management and budget. www.whitehouse/omb. Accessed 22 Feb 2011

45.

Fleck L (2006) The costs of caring: Who pays? Who profits? Who panders? Hastings Cent Rep 36(3):13–7PubMedCrossRef

46.

Murray CJL, Evans DB, Acharya A et al (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9:235–251PubMedCrossRef

47.

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–84PubMedCrossRef

48.

Garrison LP, Perez EA, Dueck A et al (2006) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. J Clin Oncol 24(18S):6023

49.

Kirkdale R, Krell J, Brown CO et al (2010) The cost of a QALY. QJM 103(9):715–20PubMedCrossRef

50.

Newby LK, Eisenstein EL, Califf RM et al (2000) Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 342(11):749–55PubMedCrossRef

51.

Rawlins MD, Culyer AJ (2004) National Institute for clinical excellence and its value judgments. BMJ 329:224. doi:10.1136/bmj.329.7459.224, (Published 22 July 2004). Accessed 13 march 2011PubMedCrossRef

52.

WHO (2000) The World Health Report 2000

53.

Tengs TO (1997) Dying too soon: how costeffectiveness analysis can save lives. Irvine, California, University of California, National Center for Policy Analysis (Policy Report no 204)

54.

Huttin C (1999) Drug price divergence in Europe: regulatory aspects. Health Aff 18:245–9CrossRef

55.

McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26(9):733–44PubMedCrossRef

56.

Cancer Trends Progress Report – 2009/2010 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, April 2010, http://progressreport.cancer.gov. Accessed 13 March 2011

57.

Faden RR, Chalkidou K, Appleby J et al (2009) Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Quarterly 87:789–819. doi:10.1111/j.1468-0009.2009.00579.x PubMedCrossRef

58.

Malvezzi M, Arfé A, Bertuccio P et al (2011) European cancer mortality predictions for the year 2011. Ann Oncol (first published online). doi:10.1093/annonc/mdq774

59.

Marrett LD, De P, Airia P et al (2008) Cancer in Canada in 2008. CMAJ 179(11):1163–70PubMedCrossRef

60.

Davis K, Schoen C, Stremkis K (2010) Mirror, mirror on the wall: how the performance of the US Health Care System Compares Internationally,MPP Commonwealth fund, June 23. Available at http://www.commonwealthfund.org/Content/Publications/Fund-Reports/2010/Jun/Mirror-Mirror-Update.aspx. Accessed 13 March 2011.

61.

Cornes P (2008) Cost-effectiveness of treating cancer anaemia. In: Nowrousian MR (ed) Recombinant human erythropoietin (rhEPO) in Clinical Oncology—Scientific and clinical aspects of anemia in cancer. 2nd Edition, Springer-Verlag, Chapter 34, pp 813–49

62.

Presentation by Andrew Dillon, the head of the National Institute for Clinical Excellence (NICE), the UK’s technology assessment agency August 04, 2008. Slides on file

63.

Raftery J (2009) NICE and the challenge of cancer drugs. BMJ 338:b67PubMedCrossRef

64.

Andrews G, Simonella L, Lapsley H et al (2006) Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis. J Rheumatol 33(4):671–80PubMed

65.

Elzawawy A (2009) The “Win-Win” initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy. World J Surg Oncol 7:44. doi:10.1186/1477-7819-7-44 PubMedCrossRef

66.

Hoverman JR, Russell S (2011) Responsible spending in cancer care: the steps that really matter. The ASCO post. January 15, Volume 2, Issue 2. Available at http://www.ascopost.com/articles/january-15-2011/responsible-spending-in-cancercare-the-steps-that-really-matter. Accessed 14 march 2011

67.

Meropol NJ, Schrag D, Smith TJ et al (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–74PubMedCrossRef

68.

How providers can lower costs and improve patient care using evidence-based medicine. An oracle white paper July 2009. Available at http://www.oracle.com/us/industries/018896.pdf. Accessed 13 March 2011

69.

US Senate Finance Committee Roundtable Proceedings on Healthcare Delivery System Reform, Allan Korn, M.D., Senior Vice President and Chief Medical Officer Blue Cross and Blue Shield Association, April 2009

70.

Schrag D, Hanger M (2007) Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 25:233–7PubMedCrossRef

71.

Mileshkin L, Schofield PE, Jefford M et al (2009) To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol 27:5830–7PubMedCrossRef

72.

Nadler E, Eckert B, Neumann PJ (2006) Do oncologists believe new cancer drugs offer good value? Oncologist 11:90–5PubMedCrossRef

73.

Cote B (2009) Oncologists: Cost-Effectiveness Policy Necessary Despite Quality of Care Warnings. Oncology Business Review. ONCBIZ.COM, September, p. 26. http://www.oncbiz.com/documents/OBR_SEPT_MRR.pdf

74.

de Joncheere K, Rietveld AH, Huttin C (2002) Experiences with generics. Int J Risk Safety Med 15:101–19

75.

Kanavos P (2007) Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin 23(1):105–16PubMedCrossRef

76.

Generic drugs in USA’s Medicare Part D saved beneficiaries and program $33 billion in 2007, says new CBO study. http://www.thepharmaletter.com/file/98437/generic-drugs-in-usas-medicare-part-d-saved-beneficiaries-and-program-33-billion-in-2007-says-new-cbo-study.html. Accessed 22 Feb 2011.

77.

Privitera MD (2008) Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 8:113–7PubMedCrossRef

78.

Market key facts. www.britishgenerics.co.uk/marketkeyfacts.htm

79.

Data from the European Generic Medicines Association. http://www.egagenerics.com/doc/fac-GxMktEur_2006.pdf

80.

Wagstaff A (2007) No-name heroes can save Europe billions. Cancerworld March–April: 24–28. Available at http://www.cancerworld.org/pdf/8503_CW17_24-28_DrugWatch.pdf

81.

Grabowski H, Cockburn I, Long G (2006) The market for follow-on biologics: how will it evolve? Follow-on biologics. Health Aff 25(5):1291–1301CrossRef

82.

Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29(4):310–2PubMedCrossRef

83.

Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411–9PubMedCrossRef

84.

Nowicki M (2007) Basic facts about biosimilars. Kidney Blood Press Res 30:267–72PubMedCrossRef

85.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM et al (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300:1887–96PubMedCrossRef

86.

Kane A (2008) Fifteen countries had banned automatic substitution of biosimilars – EGA. APM Health Europe. http://health.apmnews.com/publicsearch.php?mots=Kane&depsPage=26

87.

Schellekens H (2009) Biosimilar therapeutics—what do we need to consider? NDT Plus 2(Supp l1):i27–i36. doi:10.1093/ndtplus/sfn177 PubMedCrossRef

88.

Mody R, Goradia V, Gupta D (2011) How similar are biosimilars in India? A blind comparative study. Pharmafocusasia. Available at http://www.pharmafocusasia.com/research_development/blind-comparative-study.html. Accessed 13 March 2011

89.

Schellekens H (2004) Biosimilar epoetins: how similar are they? Eu J Hosp Pharm 3(8–12):81

90.

Arnett SO, Teillaud JL, Wurch T, et al (2011) IBC’s 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society December 5–9, San Diego, CA USA. mAbs 3(2):135–155

91.

Rossert J (2007) EMEA Guidelines on biosimilars and their clinical implications. Kidney Blood Press Res 30(Suppl 1):13–17PubMedCrossRef

92.

Sinha G (2011) EU mAb biosimilars path. Nat Biotechnol 29:10. doi:10.1038/nbt0111-10b, Published online 10 January 2011. Accessed 13 March 2011CrossRef

93.

The future of pharmaceuticals: generic medicines enhancing pharmaceutical competition and ensuring healthcare sustainability. Available at http://www.egagenerics.com/doc/ega_FuturePharmaceuticals.pdf. Accessed 13 March 2011

94.

Jelkmann W (2010) Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol 85:771–80. doi:10.1002/ajh.21805 PubMedCrossRef

95.

Tolve A (2010) Forecasting the potential of the biosimilars market. Sep 27, http://social.eyeforpharma.com/story/forecastingpotential-biosimilars-market. Accessed 13 March 2011

96.

The future of biosimilars—Market forecasts to 2015. Dec 2009. http://www.docstoc.com/docs/64933502/The-Future-of-Biosimilars—Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways. Accessed 13 March 2011

97.

Sheppard A (2010) The biosimilars market today and tomorrow. Pharm Technol Eur Volume 22, Issue 9, Sep 1. http://pharmtech.findpharma.com/pharmtech/Manufacturing/The-Biosimilars-Market-Today-And-Tomorrow/ArticleStandard/Article/detail/685049. Accessed 13 march 2011

98.

Mattison N, Mestre-Ferrandiz J, Towse A (eds) (2010) Biosimilars: How much entry and price competition will result? Office of Health Economics (OHE), London

99.

Tumulty K, Scherer M (2009) How drug industry lobbyists won on health-care. Time. Thursday, Oct 22

100.

Morrison AJ (2007) Biosimilars in the United States: a brief look at where we are and the road ahead. Biotech Law Rep 26:463–8CrossRef

101.

Grabowski H, Ridley DB, Schulman KA (2007) Entry and competition in generic biologics. Manag Decis Econ 28:439–51CrossRef

102.

Decision Resources (2011) Biosimilar erosion of branded esa market share will be more rapid in the US than in Europe. http://decisionresources.com/News-and-Events/Press-Releases/BAS-11410-(1). Accessed 13 March 2011

103.

Klusacek ME, Malecki M (2010) Biosimilars advisory service: physician perspectives on erythropoietin stimulating agents, insulin, and human growth hormone. November. http://decisionresources.com/Products-and-Services/Report?r=basxpr0610. Accessed 13 March 2011

Title: The economic pressures for biosimilar drug use in cancer medicine
Author: Paul Cornes
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue Special Issue 1/2012
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-011-0196-3

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Colony stimulating factors (CSF) biosimilars. Progress?

Risk management of biosimilars in oncology: each medicine is a work in progress

Presently available biosimilars in hematology-oncology: G-CSF

Biosimilars: Is absence of proof of difference, proof of absence of difference?

Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?

Erythropoietin biosimilars currently available in hematology-oncology